Sex differences exist in the vulnerability, incidence, manifestation, and treatment of numerous neurological and psychiatric diseases. Despite this observation prominent in the literature, little consideration has been given to possible sex differences in outcome in both preclinical and clinical research. This Mini-Review highlights evidence supporting why studying sex differences matter for advances in brain health as well as improving treatment for neurological and psychiatric disease. Additionally, we discuss some statistical and methodological considerations in evaluating sex differences as well as how differences in the physiology of the sexes can contribute to sex difference in disease incidence and manifestation. Furthermore, we review literature demonstrating that the reproductive experience in the female can render the female brain differentially vulnerable to disease across age. Finally, we discuss how genes interact with sex to influence disease risk and treatment and argue that sex must be considered in precision medicine. Together the evidence reviewed here supports the inclusion of males and females at all levels of neuroscience research. V C 2016 Wiley Periodicals, Inc.
Many neurological and psychiatric diseases, including the most frequent diseases contributing to the global burden of disease (see Table I ), are characterized by a sex difference, favoring men or women, in incidence. For example, women are more likely to present with depression (Angst et al., 2002 ) and Alzheimer's disease (Ruitenberg et al., 2001; Zhou et al., 2006) than men, whereas boys/men are more likely to present with autism (Fombonne et al., 2009; Werling et al., 2013; Idring et al., 2015) , attention deficit-hyperactive disorder (Ramtekkar et al., 2010; Rucklidge, 2010) , and Parkinson's disease than girls/women (Van Den Eeden et al., 2003; Wooten et al., 2004) . Although both sexes can be diagnosed with these diseases, the fact that these diseases can be more prevalent in one sex than the other gives researchers some biological clues about the development of the disease. Even when there is no sex difference in overall incidence of disease there may be sex differences in other aspects of the disease. As an illustration of this, although there is no sex difference in the overall incidence of schizophrenia, men are more likely to be diagnosed with schizophrenia earlier in life (late teens to twenties) whereas women are more likely to be diagnosed later in life (mid-40s; Ochoa et al., 2012) . Furthermore, men with schizophrenia present with more cognitive disturbances (Han et al., 2012) and greater reductions in temporal lobe volume than women with schizophrenia (Bryant et al., 1999) . Thus, biological sex can impact manifestation of psychiatric illness even in diseases that do not show a sex difference in prevalence. (Angst et al., 2002) Women exhibit more symptoms of depression than men and seek emotional support (Angst et al., 2002) . Atypical depression is observed in a greater proportion of women than men (Schuch et al., 2014) .
Men may respond better to tricyctic antidepressants than women (Keers & Aitchison, 2010) Men exhibit fewer symptoms and seek physical exercise or alcohol as an outlet (Angst et al., 2002) . Melancholic depression is observed in a greater proportion of men than women (Hidebrant et al., 2003) .
Women may respond better to selective serotonin reuptake inhibitors (Keers & Altchison, 2010) .
Alcohol Use Disorders 24 M>F (Ley-Ran et al, 2013) Women are more likely to be diagnosed with depression and co-morbid alcohol use disorder (Goldstein et al., 2012) . Alcohol abuse progresses more rapidly in women than in men (Randall et al., 1999) .
Women are more likely to face financial, familial, and social pressures, posing obstacles to accessing treatment (Beckman & Amaro, 1986) . These obstacles are also detrimental for pregnant women and can lead to fetal alcohol spectrum disorder. Better understanding of alcoholism in both sexes can improve the social barriers to treatment.
Men are more likely to be diagnosed with bipolar II and comorbid alcohol use disorder. (Goldstein et al., 2012) Schizophrenia 17 5
Women are diagnosed primarily between 25-35 yo and in perimenopausal period (Ochoa et al., 2012) .
Haloperidol (typical antipsychotic) or olanzapine (atypical antipsychotic) work equally well in reducing symptoms in men (Goldstein et al., 2002) . Men are more likely to be diagnosed in adolescence (15-25 yo; Ochoa et al., 2012) with schizophrenia. Men with schizophrenia show more cognitive deficits (attention, verbal memory; Goldstein et al., 1998) and smaller temporal lobes than women with schizophrenia (Bryant et al., 1999) .
Olanzapine but not haloperidol reduced symptoms in women (Goldstein et al., 2002) . Another report indicates that women overall show a greater improvement in response to antipsychotic medication than men (Usall et al., 2007) . Further research is needed to understand this.
Bipolar affective disorder 14 5
Women with bipolar 1 disorder are more likely to present with depression as their first mood episode. Women also report greater changes in weight and insomnia during the depression episode than men (Kawa et al., 2005) .
Current mood stabilizers work equally wed in men and women. However, treatment options are limited for pregnant and lactating women. (Arnold 2003) .
Men with bipolar disorder are more likely to present with mania as their first mood episode (Kawa et al., 2005 ).
Alzheimer's Disease 11 †
F>M
Women are more likely to present with comorbid anxiety and/or depression and verbal agitation (Zuidema et al., 2009) . Women exhibit more neurofibrillary tangles in the brain than men.
Women with Alzheimer's disease exhibit greater improvement to the cholinesterase inhibitors donepezil and rivastigmine than men with Alzheimer's Disease (Scacchi et al., 2014) .
Sex differences are present in the brain at the cellular, structural, and connectivity levels (Straface et al., 2012; Cahill, 2014; Ingalhalikar et al., 2014; Ruigrok et al., 2014) . The presence of X and/or Y chromosomes is of course influential at the genetic level, and gonadal hormones interact with other hormone and immune systems within the central and peripheral nervous systems as well as regulate numerous genes . It is therefore surprising that sex as a factor is not widely investigated in the literature (Beery and Zucker, 2011) , especially with regard to research in diseases which show distinct sex differences favoring men or women in incidence and/or manifestation. Despite the evidence pointing to sex differences in a variety of diseases, advances in medicine have yet to capitalize on these differences to fully advance therapeutics and disease management. Indeed, most studies have either used exclusively men or male rodent subjects or have not reported the sex of the subjects observed (Beery and Zucker, 2011) . Moreover, poor experimental design that fails to consider sex as a factor can hinder the current progress of drug advancement. As an example, AddyiV C was developed to treat hypoactive sexual desire disorder in premenopausal women. Despite this drug targeting women's sexual behavior, a study that evaluated the possible side effects of AddyiV C , including hypotension, when consuming alcohol, was assessed with only two women in a subject pool of 25 participants (Sprout Pharmaceuticals, Inc.) . This is a poor representation of the target population (women) and likely distorted the final interpretation of the side effect results. This lack of consideration for sex differences has been extensive in both preclinical and clinical research, inspiring American, Canadian, and European funding agencies to call for more women in clinical studies and female subjects in both in vivo and in vitro research (Clayton and Collins, 2014; Tannenbaum et al., 2016) . A better understanding of basic and clinical research examining sex as a factor will strengthen translation between preclinical and clinical research and ultimately will provide more information in terms of advancing disease identification and treatment in both sexes. Although sex is presently not considered a large part of precision medicine, we argue that sex of the subject is an important consideration to optimize precision medicine. This Mini-Review gives examples of how sex matters in neuroscience research, how appropriate statistical analysis is crucial for studying sex differences, and how examining reproductive experience in females and genotype contribute to a better understanding of individual differences in disease.
THE MANY FACES OF SEX DIFFERENCES
Researchers have argued convincingly that many types of sex differences are seen qualitatively, quantitatively, across populations, and in underlying mechanisms (McCarthy et al., 2012; Becker and Koob, 2016) . Qualitative sex differences are traits that are observable in one sex but not the other. One example of this type of differences is that only females have ovaries, and only men have testes. Quantitative sex differences refer to a trait present in both sexes but the magnitude of that trait expression differs by sex. For example, specific brain areas show large sex differences favoring males; as the size of the spinal nucleus of the bulbocavernosus, the central portion of the medial preoptic nucleus, and the bed nucleus of the stria terminalis are all larger in male compared with female rodents (Forger, 2006) . In addition, during sexual interactions, female rodents exhibit lordosis, whereas male rodents mount, and these behaviors occur predominantly in females and males, respectively (Veening et al., 2014) , though not exclusively (Dagg 1984) . Population sex differences are sex differences in the incidence or presentation of certain traits. Along these lines, women suffering from depression are more likely to present with comorbid anxiety than men with depression (Angst et al., 2002) . Finally, even when there are no overt sex differences in behavior and/or other underlying mechanisms, there can be sex differences in the neural representation of the behavior (McCarthy et al., 2012; Gruene et al., 2015a;  Women with Alzheimer's disease are more likely to exhibit greater impairments in cognition than men (Laws et al., 2009; Chapman et al., 2011; Irvine et al., 2012) .
However, there are presently few options for treating Alzheimer's disease for either sex. Including sex differences and genotype in drug development could greatly improve our understanding of how to treat this disease.
Men are more likely to present with aggressive behaviour and diurnal disturbances (Kitamura et al., 2012 Becker and Koob, 2016; Oberlander and Woolley, 2016) . Recent examples of this have been found in the literature (Gruene et al., 2015a; Oberlander and Woolley, 2016) . Oberlander and Woolley (2016) found that in vitro application of estradiol to CA1 pyramidal neurons of the dorsal hippocampus of adult rats had similar excitatory effects in both sexes. However, the mechanism underlying this excitation differed by sex: presynaptic glutamate release was mediated via estrogen receptor (ER)-b in females but via ERa in males. Additionally, postsynaptic sensitivity to glutamate was mediated via the G-protein-coupled ER (GPER) in females but via ERb in males. This is an example of how sex can influence differential outcome at the cellular level and highlights that the same hormone (in this case, estradiol) can have similar effects yet via different mechanistic pathways in males and females. Additionally, in an in vivo example, Gruene et al. (2015a) found that in a large cohort of male and female rodents there were no sex differences in the acquisition, extinction, or retrieval of cued fear conditioning. However, when the rodents were categorized as either "high freezing" or "low freezing," the neural representation of this behavior diverged between the sexes. The high-freezing males exhibited shorter dendritic length and more thin spines than lowfreezing males in the infralimbic neurons of the prefrontal cortex innervated by the basolateral amygdala. However, there were no morphological differences in this circuit between high-freezing or low-freezing females. This is an example of how neural circuits underlying behavior can be distinct based on sex as well as highlighting that individual differences (such as low or high freezing) can interact with sex in this regard.
NOT ALL SEX DIFFERENCES ARE DICHOTOMOUS It should be noted that some researchers have equated sex differences with sexual dimorphism (Joel, 2011) , meaning that to be considered a valid sex difference there must exist two distinct, nonoverlapping categories. Sexual dimorphism refers to two distinct forms between males and females that are apparent in one sex but never in the other. For some researchers, a true sex difference must be dimorphic, which would then suggest that the brain should give rise to nonoverlapping "male" or "female" brains. To this end, Joel et al. (2015) found that there was poor internal consistency in whether MRI measures (gray matter volume, white matter volume, and connectivity) of 10 different brain regions could be dichotomized as either male or female within each subject. The researchers did not find a strict dichotomy but observed a great deal of variability and argued effectively that human brains are mosaic rather than male or female. However, their argument extended to the idea that because there was no true male or female brain, sex would therefore play a minimal role in the brain. Although we agree with the authors that individual differences play a vital role in brain function and that our brains are mosaics of maleand female-like characteristics, the authors' conclusions regarding the importance of a lack of truly sexually dimorphic brain has been challenged by ourselves and others (Del Giudice et al., 2016; Chekroud et al., 2016) . First, this study measured sexual dimorphism on 10 separate measures within the brain as their endpoint. However, sexual dimorphism is only one type of (extreme) sex difference that can be detected. Few human organs can be considered truly sexually dimorphic (e.g., ovaries, prostate gland), and there is little reason to expect that sexual dimorphism would be found in the brain. The idea that sexual dimorphism in the brain is a necessary condition for a sex difference in the brain to be meaningful for neuroscience research appears unfounded. Indeed, the authors even point out quantitative sex differences in the brain are more influential than qualitative sex differences, so it is unclear why only qualitative sex differences were sought in this study. Del Giudice et al. (2016) further criticized this by pointing out that the concept of internal consistencies is invalid in this case because there is little internal consistency even within species and that this definition is so extreme that the hypothesis would have to be proved. Chekroud et al. (2016) used an analysis that integrated a pattern or mosaic of the morphological data from the 10 brain regions and were able to predict the sex of the individual accurately, indicating that it is the entire pattern of the brain that may generate "maleness" or "femaleness" as opposed to discretely dichotomizing each brain region. Second, the study analyzed exclusively measures of gray matter volume and white matter volume via fMRI and connectivity via diffusion tensor imaging. However, the authors' observation that there were no sex differences in gross anatomical or connectivity differences does not preclude the possibility that there are sex differences in the function of the studied region, which could yield sex differences in brain function under basal or disease states (for a further critique of this conclusion see Glezerman 2016) . As an example, there is limited evidence to suggest that the volume of the hippocampus is different between men and women when corrected for total cranial volume (Tan et al., 2016) . However, depression is characterized by a smaller hippocampal volume (McKinnon et al., 2009 ) particularly in men (Frodl et al., 2002) , and antidepressants boost hippocampal volume and neurogenesis particularly in women (Vakili et al., 2000; Epp et al., 2013) . Therefore, the argument that a lack of volumetric differences between the sexes is somehow illustrative of a lack of sex differences in brain function and disease is not relevant when considering neural function. Finally, Joel et al. (2015) also demonstrated that the majority of male brains had zero "femaleend" characteristics and the majority of female brains had zero "male-end" characteristics (Joel et al., 2015) . These findings indicate that a majority of men had few femalebrain characteristics and the majority of women had few male-brain characteristics and would support the concept of men and women exhibiting differences in the brain. As noted in the previous section, there are many types of sex differences that are not always dimorphic in nature but yet can lead to valuable information regarding basic processes and potential disease outcome in men and women.
STUDYING SEX DIFFERENCES: IMPORTANT STATISTICAL AND METHODOLOGICAL CONSIDERATIONS
Headlines from studies such as that of Joel et al. (2015) may inadvertently undermine the recent call by multiple funding agencies to include a consideration for sex differences in research and perhaps contribute to the general reluctance of the scientific community to study sex as a biological variable and/or add confusion about whether sex actually influences the outcomes of neuroscience research. This reluctance and/or confusion within the scientific community may also be partially attributed to complications at the level of statistical analyses. It is not merely the addition of females to research that will improve the present state of scientific understanding but rather every study using males and females should involve a careful statistical examination of any sex difference. One statistical concern is that some argue for using the same overall sample size that a researcher would normally use in one sex but then splitting the overall sample size into an equal ratio of males and females (McCarthy, 2015) . However, such studies would be underpowered to detect sex differences and would preclude the examination of different types of sex differences as described by Becker and Koob (2016) . Underpowered studies are a major problem in neuroscience (Button et al., 2013 ) and lead to a lack of reproducibility because of a low probability of finding a true effect. Even if a true effect is detected, low power can lead to an overestimate of the size of that effect (Button et al., 2013 ). Thus we recommend when both sexes are to be included in a study that the study be correctly powered to study possible sex differences (Button et al., 2013) .
Another statistical concern is the popular use of sex as a covariate rather than a factor. Beery and Zucker (2011) surveyed the animal and human literature from 2009 and found that those studies that identified that they had conducted research on both sexes had only analyzed sex as an independent factor 20% of the time. This suggests that 80% of studies that used both sexes either combined the sexes in their analyses or used sex as a covariate. However, important information is lost when using sex as a covariate because whether or not there is a significant effect of the covariate does not indicate whether there are nonlinear variations with sex and/or interactions of sex with treatment (Mefford and Witte, 2012) . Thus, using sex as a covariate rather than an independent factor loses important information, and studies detailed in the following sections will highlight examples of this loss of information. It is important to note that the type of statistical approach for studying sex differences will be determined by the question being addressed in any particular study. It is also important to keep in mind that some statistical approaches (e.g., linear regression or correlations) are optimal for exploring linear relationships. However, other approaches are optimal for exploring nonlinear relationships (McDonald 2014) and should be considered because hormones often have curvilinear (inverted U) associations with other variables. Thus, it is important to use statistical approaches that can capture those relationships (McDonald, 2014) .
Methodological considerations are also important when studying both sexes. For example, studies using restraint stress in rats should account for the size of a restraint tube in order for the stressor to be perceived equally between the sexes as a result of the simple fact that female rats are typically smaller than male rats. Furthermore, the sexes may differ in expression of a behavior, and behavioral tests may require different parameters or metrics to measure this. Recent examples of different expressions of behavior between the sexes are darting behaviors in females seen in response to conditioned fear (Gruene et al., 2015b) and head shakes in males seen in the forced swim test (Kokras et al., 2016) . Additionally, the vast majority of studies examining aggression has focused on the "overt aggression" (i.e., attacks) that males show when responding to a male intruder placed in their cage (so-called territorial aggression; see, e.g., Parmigiani et al., 1998) . The male bias in aggression research was due to the known male predominance in human aggression (de Almeida et al., 2015;  Investigation, 2015) and the observation that attacks in females are very uncommon. Hence females were long considered nonaggressive, except when they were defending their pups, called maternal or postpartum aggression (see, e.g., Palanza et al., 1994) . However, with detailed ethological observation of behavior, it can be demonstrated that non-lactating females also display aggression (see, e.g., Scott and Fredericson, 1951; Ferrari et al., 1996) . Laboratory female rodents perform agonistic behaviors more often than attacks, which are aimed at establishing dominance over other females. These behaviors include, following or chasing, pinning down, or aggressively grooming an intruder (Grant and Mackintosh, 1963; Clipperton-Allen et al., 2010 , 2011 . Similarly, in humans it well established that women tend to show predominantly indirect or verbal aggression, whereas males show more physical and direct aggression (Bj€ orkqvist, 1994; Vaillancourt, 2013; de Almeida et al., 2015) . Hence, the proper behaviors must be assessed when studying a phenomenon with known sex differences in its behavioral manifestations. With an ethological behavioral assessment, female CD1 mice were shown to spend at least as much (Clipperton-Allen et al., 2010) , if not more , time as males in intrasexual agonistic interactions against a same-sex intruder in their cage (Clipperton-Allen et al., 2010 , 2011 . Although males did indeed attack a same-sex intruder much more than females, females performed more dominance-related agonistic behavior than males . Thus the overall time for which the females were engaged in agonistic interactions was not less than the overall time in males. In addition, when the role of the ERs was investigated, selective activation of ERa or ERb increased sex-typical agonistic behavior in mice, i.e., attacks in males and dominancerelated behaviors in females . These results lead to the conclusion that female mice do not actually show less aggression than males but engage in different types of agonistic behaviors and, when one observes the appropriate behavior, the underlying hormonal regulation is actually similar in the two sexes. Similarly, when male-typical (physical/direct) and femaletypical (verbal/indirect) agonistic behaviors are evaluated in humans, elevated levels of sex hormones or hormone precursors are associated with enhanced competitiveness in both men and women (de Almeida et al., 2015) . Collectively, these studies exemplify the diverse ways in which sex differences can be present at many levels in neuroscience research.
Finally, it is also important to consider how endogenous changes in ovarian hormones in females (discussed further below) may account for discrepancies in preclinical research translating to clinical research. As mentioned above, depression is more prevalent in women than in men. However, when rodent models of depression, that have been validated in male subjects, were used with females they yielded mixed results, with some studies indicating that female subjects are actually resilient rather than vulnerable to depressive-like behavior (Dalla et al., 2005 (Dalla et al., , 2010 . This may be because behavioral tests of depressive phenotypes, such as sucrose anhedonia, have been optimized in male subjects but not female subjects. Sucrose palatability can fluctuate with sex and the estrous cycle with low palatability reported during low estradiol conditions (Valenstein et al., 1967; Ossenkopp et al., 1996) . Thus, if estrous cycle confounds outcome in these tests, the parameters must be optimized in females to assess behavioral phenotypes appropriately. Furthermore, if cycling female mice or rats are used, the experimental design should consider whether this is likely to influence the results if one particular phase of the estrous cycle is to be tested or if a categorization of proestrus (higher ovarian hormones)/nonproestrus (lower ovarian hormones) is sufficient. Statistically, estrous cycle phase can be handled by using it as a covariate and/or by separate analysis of females alone with phase of cycle as a separate factor. Generally, in measures of hippocampus-dependent learning or spine density in the hippocampus, it is the proestrous phase that is statistically different from the other phases. Thus, we would suggest for hippocampal measurements that a proestrus/nonproestrus distinction be made and could be used as a covariate as a first step. However, it is likely that, when tested at random, not many females will be in proestrus, so different approaches have to be used if researchers are specifically targeting estrous phase in the study. Hence, a better understanding of what contributes to modulations in performance in females is needed, including monitoring estrous cycle, for improving preclinical models of disease.
STUDYING SEX DIFFERENCES: TREATMENT
AND TREATMENT OUTCOMES An area of research that is often neglected is assessing sex differences in treatment efficacy of pharmaceutical drugs (Gartlehner et al., 2010) . It is particularly imperative for sex effects on efficacy be examined in diseases that already exhibit a sex difference in the etiology or manifestation of the disease; as this may indicate that treatment also should be different in males and females. Given that males and females have different physiological states that will ultimately influence how a drug acts and is metabolized, it is necessary to take sex and physiological state into account when evaluating the pharmacological efficacy of a drug. Indeed, sex differences in drug absorption, distribution, and elimination (Soldin and Mattison, 2009 ) have important implications for evaluating the clinical efficacy and safety of drugs. As an example, zolpidem (trade names Ambien, Intermezzo) is prescribed for insomnia and had been prescribed at equal doses for both men and women until women began reporting adverse reactions (Inagaki et al., 2010) . Greenblatt et al. (2014) reported that, when given the same dose of zolpidem as men, women had a slower clearance rate than men perhaps because of an inherent sensitivity to zolpidem in women. For this reason, the U.S. Food and Drug Administration (2013) now recommends that women be prescribed a lower dose than men. Given that dose of drug is sensitive to factors that differ by sex, such as body weight and body fat composition, clinicians have to consider sex differences when considering doses for different drugs for the safety and efficacy of patient outcome.
Efficacy may also be altered based on male and female physiology, because certain drugs may be more efficacious in one sex than the other or only efficacious in one sex but not the other. One review found that antiemetics were less efficacious in women than in men and that sexual dysfunction as a side effect of the antidepressant paroxetine affected more men than women (Gartlehner et al., 2010) . Furthermore, in the case of antipsychotics, the effects of clozapine and olanzapine are more pronounced in women than in men (Marazziti et al., 2013; Crawford and DeLisi, 2016) . Furthermore, age and hormone levels interact with antidepressant efficacy; selective serotonin reuptake inhibitors (SSRIs) have different efficacy and metabolism in older women and with and without hormone treatment in postmenopausal women (Thase et al., 2005; Ferguson and Hill, 2006) . These findings suggest that sex may influence efficacy of certain treatments and side effects of treatments, perhaps because of differences in metabolism. In preclinical research, fluoxetine is metabolized faster in female mice than in male mice (Hodes et al., 2010) . Female rats are also more sensitive to lower levels of fluoxetine; they show lower levels of immobility in the forced swim test (less depressive-like behavior) at lower doses (5 mg/kg) than male rats (Fernandez-Guasti et al., 2016) . Furthermore, gonadal hormones can facilitate some of the effects of fluoxetine to offset stress-induced depressive phenotypes in either male or female rats Wainwright et al., 2016) . However, to date, preclinical research has not yet directly compared males and females in the same experiment within a valid model of depression and antidepressant exposure.
In clinical research, sex differences in fluoxetine are apparent when considering how to improve fluoxetine efficacy. Folate deficiency has been implicated in the etiology of major depression (Young and Ghadirian, 1989) , and the therapeutic value of folate has garnered attention in neuroscience research. Although folate supplementation alone does not appear to have substantial antidepressant properties, folate supplementation is effective as an adjunct therapy to fluoxetine (Coppen and Bailey, 2000) . However, when analyzing the sexes separately, this effect was seen selectively in women and not in men. Specifically, 94% of women taking folic acid in addition to fluoxetine showed a significant reduction in Hamilton Depression Scale scores in comparison with 61% of women taking placebo and fluoxetine. Conversely, there was no significant difference in reduction in depression scores in men taking fluoxetine with adjunct folate (61% of men showed reduction in depression scores) or placebo and fluoxetine (64% of men showed reduction in depression scores). These findings illustrate how important sex as a factor can be when determining influence of treatment and how a treatment can be more valuable to one sex than to the other. This study followed the recent recommendations from the U.S. Food and Drug Administration (2014) stating that the first set of statistical analyses should determine whether there is an overall treatment effect and, if positive, only then analyze by sex. However, this order of statistical events is not effective as it could be. In fact, this may miss instances in which a drug or treatment may be efficacious in one sex but not the other. For example, in a recent randomized control trial evaluating the efficacy of progesterone after traumatic brain injury (TBI), progesterone was found to not be effective despite previous positive Phase 2 trials (Wright et al., 2007; Xiao et al., 2008) . However, the secondary analyses indicated that men were more likely to benefit from progesterone than women, although this did not reach significance (P 5 0.07; Wright et al., 2014) . The effect of progesterone being more favorable in men for TBI may interact with other factors such as severity of TBI or age of patients. Based on the present FDA recommendations, because there is no overall treatment effect, then sex differences would not be analyzed. This approach is a problem if treatment effectiveness proves to be different in one sex over another. Additionally, work from the Galea laboratory showed that, in post mortem tissue, depressed individuals taking antidepressants exhibited greater levels of neurogenesis (ratio of immature to mature neurons). Although sex was not a significant factor in main or interaction effects, an a priori analysis revealed that this antidepressant effect on immature neurons was selective to women but not to men (Epp et al., 2013) . Thus, as mentioned above, we caution against drawing conclusions based solely on analyses with both sexes collapsed into the same subject pool because vital information for one sex may be lost in this way. We recommend that sex differences be included in the statistical analyses, and, in situations in which the biological differences between men and women are reasonable a priori, justifications should be used with appropriate corrections for type I error to investigate differences between the sexes.
STUDYING WOMEN (AND MEN): INFLUENCE OF PUBERTY, AGING, AND
REPRODUCTIVE EXPERIENCE Thus far, we have discussed the necessity of treating men and women as distinct subject groups. However, it is important to consider that physiology can dramatically change across the life span with puberty onset, reproductive experience, and aging. For example, the pubertal rise in gonadal hormones coincides with an increased risk for anxiety and impulse-control disorders (Kessler et al., 2005) as well as the emergence of sex differences in depression (Ge et al., 2001) . In postpubertal women, there are cyclical fluctuations in estrogens and progesterone over the course of the menstrual cycle. These hormonal changes over the menstrual cycle correspond with changes in how psychiatric illnesses can present. As an example of this, in women suffering from schizophrenia, symptoms are exacerbated during the low-estradiol phase, implying that higher estradiol levels may protect against schizophrenic symptoms (Bergemann et al., 2002) . However, the efficacy of estrogens as an adjunct to prescribed antipsychotics is limited (Bergmann et al., 2005) . Similarly, fluctuations in ovarian hormones are implicated in mood changes related to premenstrual dysphoric disorder (Steiner et al., 2003) . Interestingly, use of oral contraceptives is associated with reduced incidence of mood disorders (Keyes et al., 2013) , although there is a stronger association with oral contraceptives based on estrogens rather than on progestins (B€ ottcher et al., 2012) . Oral contraceptives themselves can lead to reduced activity of CYP1A2, an important enzyme for clearing drugs from the system (Hilli et al., 2008) . In addition to CYP1A2, there are numerous cytochrome enzymes such as CYP3A4, CYP2D6, and CYP3c19 that are also heavily impacted by oral contraceptive use and influence drug action (Kokras et al., 2011) . For this reason, women prescribed antidepressants such as fluoxetine require a lower dose while taking oral contraceptives because higher doses result in drug accumulation in the body (Damoiseaux et al., 2014) . Menstrual cycle phase may be an important consideration for treating breast cancer; survival after curative surgery is most effective in the luteal phase of the menstrual cycle (Kucuk and Atalay, 2012) . Manipulation of ovarian hormones, such as ovarian hormone withdrawal from hormones simulated pregnancy, can also be used to induce depressive-like phenotypes in female rats (Galea et al., 2001) . Thus, both endogenous and exogenous changes in ovarian hormones can impact disease manifestation as well as treatment.
Mice and rats typically experience a 4-5-day-long estrous cycle, and these cyclical fluctuations can influence neural and behavioral outcomes. Over the course of the estrous cycle, there are fluctuations in densities of CA1 hippocampal dendritic spines, with more spines present during proestrus and estrus (high estradiol levels) but fewer during diestrus (low estradiol levels; Woolley et al., 1990 .) Additionally, estrous cycle fluctuations can interact with other systems in the brain such as the mesolimbic dopamine system (Thompson and Moss, 1997) . Female rats in proestrus were more motivated to seek cocaine as well as show enhanced cocaine self-administration in comparison with rats in diestrus, likely because of the potentiating role of estradiol on stimulant-induced dopamine release in the striatum (Becker and Cha, 1989) . In addition, when an estrous cycle effect is observed, this can indicate that sex hormones are involved and can inform further research. For example, the estrous cycle was found to affect social learning or the acquisition of adaptive information from conspecifics. Female mice displayed a socially acquired food preference for a longer time when they were in proestrus than when they were in diestrus at the time of learning and testing . Similarly, only females who were in proestrus at the time of learning still showed a socially acquired food preference when tested 24 hr later (as reported by S anchez- Andrade et al., 2005) . Because proestrus is the phase of the estrous cycle with high circulating estradiol levels, these results suggest that estrogens promote social learning. This was indeed demonstrated, with 17b-estradiol rapidly enhancing the social transmission of food preferences (Ervin et al., 2015) . This effect of estrogens appears mediated by the GPER for rapid effects (Ervin et al., 2015) and ERb for long-term effects of estrogens (Clipperton et al., 2008) . One concern is that the additional workload of monitoring the estrous cycle daily may deter researchers from including female subjects. We emphasize that monitoring estrous cycle when relevant, and using it as a factor when it is appropriate for the original research question, is important rather than losing valuable information by simply not including female subjects. Thus, it may not be as necessary to monitor estrous cycle daily during a 6-week chronic paradigm because the animal will cycle through many stages during the experiment presumably, but it will be necessary to determine phase of estrous cycle in females in acute studies, during behavioral testing, and at the time of tissue collection.
Another biological event that is uniquely female includes pregnancy and the postpartum period, which are characterized by distinct physiological changes as well as greater vulnerability to psychiatric illness. During pregnancy, high concentrations of steroid and peptide hormones are secreted from the placenta, an endocrine gland generated during pregnancy (Hendrick et al., 1998) . After parturition and into the postpartum period, steroid and peptide hormone levels plummet with the expulsion of the placenta and remain low throughout most of the lactation period (Brett and Baxendale, 2001) . Along with changes to levels of estrogens and progesterone in women, there are dramatic alterations to the stress hormone system. Basal levels of glucocorticoids gradually increase over the course of pregnancy and remain high during lactation (with its high metabolic burden), whereas the HPA axis becomes unresponsive to acute stressors (Brunton and Russell, 2008) . Given these dramatic hormone alterations, it is perhaps not surprising that the female brain changes during pregnancy and postpartum. In fact, by parturition, the maternal brain shrinks by 8% and reverts to its original volume by 6 months postpartum (Oatridge et al., 2002) . Thus, pregnancy and the postpartum period can impact the brain, and this may have functional implications for psychiatric illness at this time. These reproductive events should be highlighted in neuroscience research to advance women's health. For example, a majority of women (approximately 80%) experience mild and transient mood changes or "baby blues" after childbirth. However, more severe mood disruptions can also arise at this time. Prenatal depression affects approximately 12% of pregnant women (Bennett et al., 2004) , and postnatal depression affects approximately 10-15% of postpartum women (Gavin et al., 2005) . Even more concerning, 40% of mothers experiencing postnatal depression are developing their first bout of depression (Wisner et al., 2013) . Although depression during pregnancy is a strong predictor of postnatal depression, prenatal and postnatal depression can occur in isolation (O'Hara and McCabe, 2013) . The aforementioned physiological changes that differ between pregnancy and postpartum may then suggest that the biological circuits underlying depression occurring solely in pregnancy are different from those underlying depression occurring solely in the postpartum. More research directed toward understanding the diverging and converging mechanisms of depression outside of pregnancy, during pregnancy, and during the postpartum period (O'Hara and McCabe, 2013) will better inform our understanding of maternal depression, and, given that there are marked physiological changes during these periods, it is entirely possible that treatment would have to be altered.
Treating maternal depression has been complicated by a poor understanding of depression at this time as well as the unique physiology of women during this time. Maternal depression is classified as depression occurring during pregnancy and within the first 4 weeks of the postpartum period (DSM 5), although the greatest incidence of depression occurs 2-3 months postpartum (Gavin et al., 2005) . As noted above, marked changes in steroid and peptide hormones from pregnancy throughout the postpartum period may complicate treatment and diagnosis. Indeed, treating maternal depression is challenging because antidepressant efficacy is limited in pregnancy and postpartum (DeCresenzo et al., 2014) . Generally, mothers suffering from depression are prescribed the same antidepressants that are used to treat major depression in men and women. Research from the Galea laboratory showed that maternal fluoxetine during the postpartum period was unable to prevent glucocorticoid-induced depressivelike behavior and reduction in hippocampal neurogenesis in dams, unlike the case in nulliparous rats (Workman et al., 2016) . Thus differences in drug efficacy during the postpartum period may not be surprising given that steroid and peptide hormones, metabolism, and the brain change during pregnancy and postpartum (Brett and Baxendale, 2001 ).
Finally, motherhood can moderate disease risk and, perhaps, treatment well beyond the time of reproduction. Untreated postpartum depression results in a fourfold increased risk for depression after the postpartum period, resulting in a life-long burden of disease (Joseffson and Sydsko, 2007) . Even much later in life, reproductive experience increases risk for Alzheimer's disease in women but not men (Ptok et al., 2002) . Interestingly, research from the Galea laboratory showed that, in middle-aged female rats with no reproductive experience, hippocampal cell proliferation was not significantly affected by acute estradiol or estrone administration (Barha and Galea, 2011) . However, in multiparous middle-aged female rats, exposure to either estradiol or estrone increased hippocampal cell proliferation. This highlights that, even long after mothers are pregnant or actively raising pups, the experience of motherhood can render the brain more sensitive to the effects of estrogens. This has important implications for preclinical research in terms of taking reproductive experience into account because this may play a moderating role in neural processes. This also has important clinical implications in terms of how reproductive experience may be an additional factor in the relationship among sex, genotype, and disease outcome.
STUDYING SEX DIFFERENCES: GENOTYPE
INTERACTIONS AND INDIVIDUAL DIFFERENCES Men and women differ in genotypes, which is expressed in every cell in the body (de . There are sex differences in how the genome is read (Ellegren and Parsch, 2007; Bellott et al., 2014) and in the epigenetic modification of gene expression (Shen et al., 2015) . Sex interacts with Val66Met polymorphisms of the brain-derived neurotrophic factor (BDNF) gene to influence loneliness in adolescence (Verhagen et al., 2014) , stroke rehabilitation (Mirowska-Guzel et al., 2014) , and regional cerebral blood flow in the prefrontal cortex and hippocampus (Wei et al., 2012) . These sex-by-genotype interactions may be especially relevant for diseases such as major depression that are complicated by heterogeneous presentation. Women are more likely than men to present with major depressive disorder (Schuch et al., 2014) . However, the presentation of major depressive disorder diverges between the sexes. Women with major depression are more likely to endorse symptoms such as depressed mood, sleep disturbances, somatic and gastrointestinal complaints, and changes in weight than men (Angst et al., 2002; Schuch et al., 2014) . Furthermore, women with depression are more likely to present with either comorbid anxiety or have greater lifetime prevalence of anxiety than men (Young et al., 2009; Schuch et al., 2014) . However, men with major depression are more likely to present with comorbid alcohol or substance abuse and endorse symptoms related to anhedonia (Angst et al., 2002; Schuch et al., 2014) . Women are more likely than men to present with either atypical and melancholic depression, however, a greater proportion of men have melancholic depression, whereas a greater proportion of women have atypical depression (Hildebrandt et al., 2003) . Subtypes of depression differ in their biological, inflammatory, and metabolic correlates (Lamers et al., 2013) . Although both sexes may still be diagnosed with either of these subtypes of depression, melancholic depression was associated with the long allele of the serotonin transporter-linked polymorphic region (5-HTTLPR) of SLC6A4 (serotonin transporter gene) particularly in women and not in men (Baune et al., 2008) . Even within women, the AA variant of the ESR2 gene for ERb was associated with increased risk for lifetime depression compared with other polymorphisms of the same gene (Keyes et al., 2015) . Polymorphisms of the ESR1 gene for ERa also interacted with postmenopausal hormone treatment to increase depression risk selectively among homozygous T-allele carriers (Keyes et al., 2015) . More studies such as these will improve our understanding of how major depression is manifested differently in men and women in the clinical population.
If individual differences related to sex and genotype are apparent in the presentation of disease, then treating these diseases should take into account individual differences. For example, in continuing to examine the case of major depression, prescribed antidepressants initially provide relief for only 33% of patients and cumulatively for 67% of patients , and, among those who respond to treatment, 57% will experience relapse because of a failure in continual drug efficacy (Byrne and Rothschild, 1998) . The fact that only a subset of the clinically depressed population responds to these treatments that specifically target the monoamine system suggests that perhaps this system is not the primary site of pathology in all depressed patients. There are sex differences in serotonin synthesis and content (Carlsson and Carlsson, 1988; Nishizawa et al., 1997) . Additionally, men have more serotonin reuptake binding sites (which antidepressants specifically target) than women in the thalamus, insula, and hippocampus (Jovanovic et al., 2008) , which may impact antidepressant efficacy. Collectively, these studies indicate that sex and genotype may be contributing factors in antidepressant inefficacy, particularly for SSRIs, and also highlight that sex may play an important role in the field of pharmacogenetics. These findings represent an opportunity to connect sex, genotype, and even multiple theories describing depression (serotonin, stress, glutamate, etc.) into a novel way of investigating the disease and may improve our ability to understand treatment of depression and other psychiatric diseases.
CONCLUSIONS
The evidence reviewed here points to a crucial role for considering the role of sex differences in disease manifestation and treatment in both preclinical and clinical research. Prioritizing sex differences in neuroscience research will require specific alterations to current research methods. For instance, we reviewed how fluctuations in ovarian hormones can contribute to behavioral and neural changes that may be important for treating brain disease. There is a misleading conception that only female subjects experience these hormone fluctuations, unlike male subjects. However, men show marked alterations in testosterone levels across the day (Diver et al., 2003) , with increasing age (Zirkin and Tenover, 2012) and seasonally (Moffat and Hampson, 2000) . These alterations in levels of testosterone may be associated with variations in cognitive performance in men (Holland et al., 2011) and are related to changes in fMRI activity patterns (Sch€ oning et al., 2007) . It is currently not known whether circulating levels of testosterone in men or estradiol in women show similar or different effect sizes for brain activation and/or cognition. Other endogenous ovarian hormone changes such as those observed in pregnancy and BOX 2. IMPORTANT CONSIDERATIONS FOR SCIENTISTS Data demonstrating an absence of a sex difference are as important as data demonstrating a sex difference. If an experimental manipulation results in male and female subjects being equally affected, that is a vital contribution to neuroscience research; it may suggest converging mechanisms for both sexes. Alternatively, a lack of sex difference in behavior might not reflect a lack of sex differences at the mechanistic level or in neural manifestations. Thus, we caution researchers against discarding data or withholding reporting of a lack of sex differences. Monitoring estrous cycle is an important contribution to understanding female performance. We urge researchers to monitor estrous cycle when necessary. For preclinical research modeling diseases, if the disease has a sex difference, then the model should also consider incorporating both sexes into the research unless a proper justification can be provided for using one sex instead of the other. Using sufficient sample sizes of males and females as well as using sex as a factor instead of a covariate is important for better understanding disease and disease processes. This does not necessitate that all research use both sexes. Rather, if both sexes are being used, published research should use appropriate sample sizes, specify how many males and how many females were used. This is necessary for in vitro, preclinical, and clinical research. Presentation and treatment of some disease are altered by hormonal milieu as well as reproductive experience. There is a need for more research on how the brain changes during and after reproductive experience as well as how to how to improve treatments targeting maternal mental health. Evaluating sex differences in preclinical models will have to prioritize this aspect in the methods of the experiment. As an example of this, in evaluating aggression in rodents, the territorial aggressive behaviors that males exhibit are unlike the agnostic behavior that females exhibit. Thus, studies attempting to delineate sex differences in aggression should incorporate these differences into the methods of the experiment in addition to maintain sufficient sample size of both sexes. BOX 1. IMPORTANT CONSIDERATIONS FOR SCIENCE POLICY Limited consideration for sex differences is contributing to the poor translation between preclinical and clinical research. Given that many diseases are characterized by a sex difference in prevalence and/or manifestation, there is a need to include a consideration for sex in the etiology, and treatment of disease. Men and women are biologically different, and research should appropriately and accurately consider sex differences. The present set of FDA recommendations to analyze for sex differences only if an overall treatment effect are a problem insofar as sex differences may be erroneously neglected via this statistical method (U.S. Food and Drug Administration, 2014). We recommend that, when including both sexes in the experiment, every statistical analysis use sex as a factor and not as a covariate throughout all analyses. Studying sex differences is not the same as improving women's health research. There is a need for funding and researching how physiology over the life span interacts with the brain. For instance, maternal mental health is underrecognized and should be prioritized. Pregnancy and the postpartum period are sensitive and vulnerable times for women to present with psychiatric illnesses. The physiological changes of pregnancy and postpartum in women are dramatically different from those of cycling women, which likely affects drug action and metabolism. Thus, there is a need for funding research to study disease to inform mothers better as well as clinicians for how best to treat these illnesses. postpartum result in permanent changes to the maternal brain. This has important implications for factoring reproductive experience for disease risk. Moreover, exogenous hormone changes via hormone replacement therapy may interact with these changes and influence disease outcome. Thus, fluctuating hormone levels are an important consideration for male and female research.
Consideration of sex differences, sex hormones, reproductive experience, and genetic differences will better inform precision medicine options. As neuroscience research advances and prioritizes individual differences, the current one-size-fits-all treatment approach for all psychiatric diseases seems na€ ıve. Studies investigating how sex and genotype interact will have important implications for understanding disease manifestation and treatment over the life span for both males and females. Ultimately, unraveling the complex etiology of psychiatric diseases as well as optimizing treatments will be improved by including sex and genotype in understanding physiology, treatment ramifications, and disease susceptibility.
